AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33248986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimlanod 12 μg/kg/min
Number of subjects: 322
Study 33248986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 33248986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimlanod
Number of subjects: 322
Study 36245835 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut embedding plus warm needle moxibustion
Number of subjects: 120
Study 36245835 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium sustained-release tablet (100 mg) once a day for 8 courses (7 days each course)
Number of subjects: 120
Study 35110346 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL)
Number of subjects: 166
Study 35110346 — intervention group
Group type: COMPARATOR
Intervention: Expert-assisted learning (EAL)
Number of subjects: 166
Study 34095297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on smoking status, waist circumference, hemoglobin A1c, and fasting blood glucose
Number of subjects: 2741
Study 33034564 — intervention group
Group type: EXPERIMENTAL
Intervention: App with personalized coaching
Number of subjects: 129
Study 33034564 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 129
Study 33034564 — intervention group
Group type: EXPERIMENTAL
Intervention: App only
Number of subjects: 129
Study 35665288 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate combined with labetalol
Number of subjects: 500
Study 35665288 — intervention group
Group type: COMPARATOR
Intervention: Conventional magnesium sulfate
Number of subjects: 500
Study 36014905 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg consumption
Number of subjects: 155
Study 36014905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no egg consumption)
Number of subjects: 155
Study 34462343 — intervention group
Group type: EXPERIMENTAL
Intervention: CC with telemedicine
Number of subjects: 422
Study 34462343 — intervention group
Group type: COMPARATOR
Intervention: CC alone
Number of subjects: 422
Study 35439246 — intervention group
Group type: EXPERIMENTAL
Intervention: P2S program (intervention group, n = 199; 28 lost at follow-up)
Number of subjects: 399
Study 35439246 — intervention group
Group type: EXPERIMENTAL
Intervention: P2S program (intervention group)
Number of subjects: 399
Study 35439246 — intervention group
Group type: COMPARATOR
Intervention: Generic health websites (control group, n = 200; 15 lost at follow-up)
Number of subjects: 399
Study 32761487 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (BE) for 12 weeks
Number of subjects: 110
Study 32761487 — intervention group
Group type: COMPARATOR
Intervention: Usual physical exercise (control group) for 12 weeks
Number of subjects: 110
Study 34419082 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg·day−1)
Number of subjects: 19
Study 33022148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal music listening
Number of subjects: 83
Study 33022148 — intervention group
Group type: COMPARATOR
Intervention: Instrumental music
Number of subjects: 83
Study 33022148 — intervention group
Group type: COMPARATOR
Intervention: Audiobooks
Number of subjects: 83
Study 35467228 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based motivational interviewing sessions (5 weekly sessions)
Number of subjects: 100
Study 35467228 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 100
Study 35467228 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based motivational interviewing
Number of subjects: 100
Study 34493319 — intervention group
Group type: EXPERIMENTAL
Intervention: liso-cel
Number of subjects: 256
Study 33502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (ST) plus belimumab 10 mg/kg
Number of subjects: 1684
Study 33502473 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) alone
Number of subjects: 1684
Study 33502473 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI-4 responders
Number of subjects: 1684
Study 33502473 — intervention group
Group type: COMPARATOR
Intervention: SRI-4 non-responders
Number of subjects: 1684
Study 33502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on belimumab 10 mg/kg in antimalarial users
Number of subjects: 1684
Study 33502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on belimumab 10 mg/kg in anti-dsDNA positive patients
Number of subjects: 1684
Study 33502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on belimumab 10 mg/kg in anti-Sm positive patients
Number of subjects: 1684
Study 32075307 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified OTAGO Exercise Program (8 weeks, 3 times a week)
Number of subjects: 34
Study 32075307 — intervention group
Group type: COMPARATOR
Intervention: Regular activities (Control Group)
Number of subjects: 34
Study 33621815 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) including routine monthly counseling, individual face-to-face health counseling (1 h/month), and remote counseling (at least twice per month).
Number of subjects: 155
Study 33621815 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received routine monthly counseling.
Number of subjects: 155
Study 33621815 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) for participants with seizure frequency of ≥1 per year.
Number of subjects: 155
Study 33621815 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) for participants with seizure frequency of <1 per year.
Number of subjects: 155
Study 33621815 — intervention group
Group type: COMPARATOR
Intervention: Self-management intervention (SMI) and control group (CG) comparison.
Number of subjects: 155
Study 35305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 10 units (IM group)
Number of subjects: 210
Study 35305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 10 units in 100 ml 0.9% NaCl solution over 10-15 min (IV group)
Number of subjects: 210
Study 35305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IV + IM regimens (IV + IM group)
Number of subjects: 210
Study 33982512 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic TCM prescriptions
Number of subjects: 0
Study 33982512 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled evidence-based studies
Number of subjects: 0
Study 33982512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical registration studies
Number of subjects: 0
Study 35472696 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy Challenge Alcohol Literacy Curriculum (ECALC)
Number of subjects: 48
Study 35472696 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control presentation
Number of subjects: 48
Study 33223020 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 33223020 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost SRS after fractionated radiation therapy
Number of subjects: 0
Study 33223020 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with SRS
Number of subjects: 0
Study 33406064 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cytoreduction
Number of subjects: 0
Study 33406064 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum/taxane‐based chemotherapy
Number of subjects: 0
Study 33406064 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive cytoreductive procedures
Number of subjects: 0
Study 33406064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative heated intraperitoneal chemotherapy
Number of subjects: 0
Study 34802253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 34802253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 33272675 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised machine learning virtual screening procedure
Number of subjects: 777
Study 33272675 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro and in vivo assays of selected pesticides
Number of subjects: 777
Study 33272675 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening of pesticides for AhR activity
Number of subjects: 777
Study 33196806 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (clinician's choice of Ringer lactate solution or Plasma‐Lyte A solution)
Number of subjects: 172
Study 33196806 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Number of subjects: 172
Study 34374114 — intervention group
Group type: EXPERIMENTAL
Intervention: MB02 (3 mg/kg intravenous dose)
Number of subjects: 114
Study 34374114 — intervention group
Group type: COMPARATOR
Intervention: US-bevacizumab (3 mg/kg intravenous dose)
Number of subjects: 114
Study 34374114 — intervention group
Group type: COMPARATOR
Intervention: EU-bevacizumab (3 mg/kg intravenous dose)
Number of subjects: 114
Study 34374114 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (MB02, US-bevacizumab, EU-bevacizumab)
Number of subjects: 114
Study 34086595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy Self-management Telehealth (OSMT) intervention
Number of subjects: 93
Study 34086595 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth engineering support
Number of subjects: 93
Study 36163694 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly home-based physiotherapy for 12 weeks facilitating 100 minutes/week of moderate-intensity walking
Number of subjects: 38
Study 36163694 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 38
Study 33439309 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported moderate-to-vigorous physical activity
Number of subjects: 377234
Study 33439309 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vigorous physical activity
Number of subjects: 377234
Study 33439309 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceleration average
Number of subjects: 377234
Study 33439309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction of accelerations
Number of subjects: 377234
Study 33332189 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) plus etoposide
Number of subjects: 417
Study 33332189 — intervention group
Group type: COMPARATOR
Intervention: Chemoconditioning (fludarabine, thiotepa, and either busulfan or treosulfan)
Number of subjects: 417
Study 33332189 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Number of subjects: 417
Study 33059741 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared follow-up care intervention (EMINENT)
Number of subjects: 60
Study 33059741 — intervention group
Group type: COMPARATOR
Intervention: Usual, specialist-led, follow-up care
Number of subjects: 60
Study 35045416 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (EVE)
Number of subjects: 22
Study 35045416 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (TKI)
Number of subjects: 22
Study 35045416 — intervention group
Group type: COMPARATOR
Intervention: Both EVE and TKI
Number of subjects: 22
Study 34472897 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 179
Study 34472897 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) technical skills
Number of subjects: 179
Study 34472897 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex reflections in MI
Number of subjects: 179
Study 32782254 — intervention group
Group type: EXPERIMENTAL
Intervention: Queens choosing between two empty nesting chambers; no specific dosage or duration mentioned.
Number of subjects: 0
Study 36147577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA/MET (CANA 100 mg once daily plus MET 1000 mg twice daily)
Number of subjects: 51
Study 36147577 — intervention group
Group type: COMPARATOR
Intervention: MET (MET 1000 mg twice daily)
Number of subjects: 51
Study 36147577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA/MET
Number of subjects: 51
Study 36147577 — intervention group
Group type: COMPARATOR
Intervention: MET
Number of subjects: 51
Study 33077301 — intervention group
Group type: EXPERIMENTAL
Intervention: Liq PCV‐free HRV
Number of subjects: 1272
Study 33077301 — intervention group
Group type: COMPARATOR
Intervention: Lyo HRV
Number of subjects: 1272
Study 33158396 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro expression training software
Number of subjects: 55
Study 33158396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 55
Study 35575053 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative expression program (CrExp, n = 18)
Number of subjects: 36
Study 35575053 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 18)
Number of subjects: 36
Study 33287713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard anti-TB treatment
Number of subjects: 80
Study 35473643 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participation in the planning and implementation of the Trial
Number of subjects: 173
Study 35473643 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participation skills training and support
Number of subjects: 173
Study 35473643 — intervention group
Group type: EXPERIMENTAL
Intervention: Long process of relationship building between stakeholders
Number of subjects: 173
Study 33775499 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician self-disclosure
Number of subjects: 244
Study 33775499 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician self-disclosure (female physicians)
Number of subjects: 244
Study 33775499 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician self-disclosure (male physicians)
Number of subjects: 244
Study 35811716 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm based on the pCO2 gap and P(v–a)CO2/C(a–v)O2 ratio
Number of subjects: 180
Study 35811716 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice
Number of subjects: 180
Study 32112730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelabor screening test combining cerebroplacental ratio and maternal placental growth factor
Number of subjects: 501
Study 32112730 — intervention group
Group type: COMPARATOR
Intervention: Routine obstetric care (Control)
Number of subjects: 501
Study 32112730 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-positive women
Number of subjects: 501
Study 36004732 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (AT) within 2 months
Number of subjects: 190
Study 36004732 — intervention group
Group type: COMPARATOR
Intervention: Routine adenotonsillectomy (AT) after 12 months
Number of subjects: 190
Study 36004732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and routine AT
Number of subjects: 190
Study 33937960 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia
Number of subjects: 80
Study 33937960 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 80
Study 32208231 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) treatment
Number of subjects: 50
Study 35194648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (once-daily)
Number of subjects: 58
Study 34487346 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat treatment (Imm+H) using pulsed shortwave diathermy for 2 hours daily for 10 days
Number of subjects: 21
Study 34487346 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Imm)
Number of subjects: 21
Study 34487346 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 21
Study 34847453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based program (2 hours, twice a week for three consecutive weeks)
Number of subjects: 45
Study 34847453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nature-based program)
Number of subjects: 45
Study 32199446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine autoinjectors
Number of subjects: 0
Study 32199446 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringes
Number of subjects: 0
Study 33888247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment
Number of subjects: 8828
Study 33888247 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment
Number of subjects: 8828
Study 36563830 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent local anesthesia (TLA)
Number of subjects: 70
Study 36563830 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 70
Study 33389770 — intervention group
Group type: EXPERIMENTAL
Intervention: SSB behavioural intervention
Number of subjects: 100
Study 32945875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (motivational enhancement therapy and cognitive behavioral therapy, 6 in-person sessions of 1 hour each and 3 optional group sessions)
Number of subjects: 440
Study 32945875 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (similar components as combined intervention but consisting of 2 shorter in-person sessions and 2 telephone sessions)
Number of subjects: 440
Study 32945875 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 440
Study 32945875 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 440
Study 32945875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 440
Study 32915099 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐DRSEQ‐SRA in the non‐drinking group
Number of subjects: 406
Study 32915099 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐DRSEQ‐SRA
Number of subjects: 406
Study 33978699 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavioral therapy (ICBT) for 10 weeks.
Number of subjects: 103
Study 33978699 — intervention group
Group type: COMPARATOR
Intervention: Therapist-guided internet-delivered supportive therapy (ISUPPORT) for 10 weeks.
Number of subjects: 103
Study 33978699 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness analysis for ICBT vs ISUPPORT.
Number of subjects: 103
Study 32584279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 105
Study 32584279 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic bite wafer
Number of subjects: 105
Study 32584279 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 105
Study 32584279 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study 36468512 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietene ProGrip self‐fixing mesh (PG)
Number of subjects: 141
Study 36468512 — intervention group
Group type: COMPARATOR
Intervention: Lightweight standard mesh (LS)
Number of subjects: 141
Study 33560877 — intervention group
Group type: EXPERIMENTAL
Intervention: PTR plus chemotherapy
Number of subjects: 165
Study 33560877 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 165
Study 36498519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 micrograms)
Number of subjects: 52
Study 36498519 — intervention group
Group type: COMPARATOR
Intervention: Single‐shot femoral nerve block (SSFNB)
Number of subjects: 52
Study 36498519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 52
Study 33211860 — intervention group
Group type: EXPERIMENTAL
Intervention: CR6261 (50 mg/kg)
Number of subjects: 91
Study 33211860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 33568600 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable cement/screw-retained design (RCSRD) metal copings
Number of subjects: 20
Study 33568600 — intervention group
Group type: COMPARATOR
Intervention: Cement-retained (CR) metal copings
Number of subjects: 20
Study 35311678 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGRESS website
Number of subjects: 217
Study 33156201 — intervention group
Group type: COMPARATOR
Intervention: Zuspan regimen (4‐g IV loading dose, then a 1‐g/h infusion)
Number of subjects: 37
Study 33156201 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate regimen (6‐g IV loading dose, then a 2‐g/h infusion)
Number of subjects: 37
Study 36227672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping moxibustion combined with oral montmorillonite powder
Number of subjects: 51
Study 36227672 — intervention group
Group type: COMPARATOR
Intervention: Oral montmorillonite powder
Number of subjects: 51
Study 34266454 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 310
Study 34266454 — intervention group
Group type: COMPARATOR
Intervention: non-COVID-19 ARDS
Number of subjects: 310
Study 34266454 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS with heat and moisture exchangers
Number of subjects: 310
Study 34955301 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMPALL intervention (five-session, 540 min, multidomain, audiovisually aided, therapist-facilitated)
Number of subjects: 36
Study 34955301 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 33039994 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Parenting Acceptance and Commitment Therapy (Early PACT)
Number of subjects: 60
Study 33039994 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study 36004553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application in addition to standard follow-up care
Number of subjects: 670
Study 36004553 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 670
Study 33577139 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) after electrode implantation
Number of subjects: 14
Study 33577139 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (blinded subgroup)
Number of subjects: 14
Study 34144680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low APTI (73,000 kPa·s)
Number of subjects: 10
Study 34144680 — intervention group
Group type: EXPERIMENTAL
Intervention: High APTI (73,000 × 1.5 kPa·s)
Number of subjects: 10
Study 34144680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both APTI stimuli
Number of subjects: 10
Study 35307775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based dyadic intervention
Number of subjects: 34